Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
OmicsWay Corp.
With
Oncobox Ltd., Russia
Vitamed LLC, Russia
Republican Oncological Dispensary of Karelia Republic, Russia
Biopsy and/or surgical samples from Her2-positive breast cancer patients treated with Trastuzumab alone or in combinations with other regimens of chemotherapy with known clinical outcomes will be collected and subjected to mRNA sequencing. Expression profiles will be analysed using original bioinformatic platform Oncobox. Based on comparison of molecular pathways activation strength and clinical response to Trastuzumab and chemotherapy, this study aims to identify molecular markers predicting efficacy of therapy with Trastuzumab and the possibility of further relapse.
Age
18–80
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
adult females
histologically confirmed HER2-positive breast cancer
available FFPE samples of breast cancer tissue
patients treated with Trastuzumab alone or in combination(s) with other regimens of chemotherapy with known outcome according to RECIST 1.1
stage II or more
patients who have signed an informed consent
You may not be if
less than 70% of intact tumor cells in available FFPE samples
Clareo Health | Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer
